View in EDS

ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib.

Saved in:
Bibliographic Details
Title: ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib.
Authors: Thunnissen, E.1 (AUTHOR) e.thunnissen@amsterdamumc.nl, Lissenberg-Witte, B.I.2 (AUTHOR), van den Heuvel, M.M.3 (AUTHOR), Monkhorst, K.4 (AUTHOR), Skov, B.G.5 (AUTHOR), Sørensen, J.B.6 (AUTHOR), Mellemgaard, A.7 (AUTHOR), Dingemans, A.M.C.8 (AUTHOR), Speel, E.J.M.9 (AUTHOR), de Langen, A.J.10 (AUTHOR), Hashemi, S.M.S.10 (AUTHOR), Bahce, I.10 (AUTHOR), van der Drift, M.A.11 (AUTHOR), Looijen-Salamon, M.G.12 (AUTHOR), Gosney, J.13 (AUTHOR), Postmus, P.E.14 (AUTHOR), Samii, S.M.S.15 (AUTHOR), Duplaquet, F16 (AUTHOR), Weynand, B.17 (AUTHOR), Durando, X.18 (AUTHOR)
Source: Lung Cancer (01695002). Dec2019, Vol. 138, p13-18. 6p.
Database: Academic Search Ultimate
Description
ISSN:01695002
DOI:10.1016/j.lungcan.2019.09.023